From DCAT Value Chain Insights (VCI)
Repligen Corporation, a life-sciences company focused on the development and commercialization of consumable products used in biomanufacturing, has named Tony J. Hunt to be the company's next chief executive officer (CEO). Mr. Hunt, currently Repligen's chief operating officer (COO), will succeed Walter C. Herlihy, who will retire as president and CEO effective May 21, 2015, the date of the company's annual meeting of stockholders.
Prior to his role as COO at Repligen, Mr. Hunt was president of bioproduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed in February 2014. He joined Life Technologies in 2008 as general manager, bioproduction chromatography and pharma analytics, and played a key role in the development and growth of the company's bioprocessing business. From 2000 to 2008, he held a number of positions at Applied Biosystems, including senior director, pharma programs, where he launched the pharma analytics business that in 2008 became a part of the bioproduction platform at Life Technologies.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription